Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on BLUR GROUP PLC. We currently have 22 research reports from 2 professional analysts.
|27Feb17 07:00||RNS||blur engaged with Top 100 UK law firm|
|08Feb17 07:00||RNS||Q4 2016 Quarterly Business Update|
|21Dec16 07:00||RNS||Grant of Options|
|06Dec16 09:04||RNS||Holding(s) in Company|
|16Nov16 10:19||RNS||Holding(s) in Company|
|16Nov16 10:18||RNS||Holding(s) in Company|
|03Nov16 07:00||RNS||Q3 2016 Quarterly Business Update|
Frequency of research reports
Research reports on
BLUR GROUP PLC
BLUR GROUP PLC
N+1 Singer - Morning Song 08-02-2017
08 Feb 17
blur Group (BLUR LN) Trading update and first enterprise subscription | First Derivatives (FDP LN) Strategic investment partnership, target price increased | Grainger (GRI LN) Positive start to FY17e, rental growth continues | Victrex (VCT LN) Solid Q1, shine taken off by medical
N+1 Singer - blur Group - Trading update and first enterprise subscription
08 Feb 17
Q4 saw a period of further improvements to EBITDA, costs and cash burn. FY 2016 EBITDA is expected to be ahead of expectations and cash at year-end stood at $2.5m. More significantly, the group announced its first 12-month subscription to the Group buyer plan, taken up by a Top 100 UK-based law firm. This will allow the customer to transact an annual spend value of up to $2m through blur’s platform. This is a key milestone for the group who has been focused on converting enterprise customers to adopt its platform to transform their indirect spending. The market opportunity is significant and its proposition resonates well with a market looking for solutions for spend control and risk management. Successful execution on this relationship will point towards the scalable and sustainable growth path the group is looking to secure.
Small Cap Breakfast
08 Feb 17
Arix Bioscience — Intention to float on the main market from the global healthcare and life science Company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.
N+1 Singer - Morning Song 03-11-2016
03 Nov 16
blur Group (BLUR LN) Q3 trading update | Earthport (EPO LN) Approval for outbound services for banks in India | Eckoh (ECK LN) Appointment of new CFO | H&T Group (HAT LN) FY16e to exceed expectations on impact of higher H2 gold price | Howden Joinery Group (HWDN LN) In line FY16 but strengthening headwinds result in FY17 downgrades | Low & Bonar (LWB LN) Solid Update | SDL (SDL LN) Disposal of campaigns business; more to come | Spirent Communications (SPT LN) Progress but revenue remains lumpy | Wilmington Group (WIL LN) Q1 In-line
N+1 Singer - NCC Group - Further issues in Assurance
22 Feb 17
NCC released a trading update yesterday afternoon highlighting further issues in its Assurance division. Sales growth has been lower than expected in all regions, resulting in a significant reduction in full year expectations. We have reduced our EPS forecasts by 25% in FY’17 and 22%/25% in FY’18/’19 respectively. Escrow continues to perform in line with expectations. In response to these issues the Board has announced a strategic review into all of the Assurance businesses. The results of the strategic review are expected to be announced at the FY results in July. With an extended period of uncertainty on the horizon we believe it will be hard for investors to gain confidence in NCC in the short term. That said we see fundamental value in the stock. Escrow is unaffected by this warning and remains an extremely high quality business, which we value at £353m in our SOTP. At the current share price this leaves Assurance valued at c.5x cal’17 EBITDA. While this appears to be an attractive multiple for a rare cybersecurity asset, we would like further clarity on the underlying nature of the current issues, hence our Hold recommendation. Our 138p target price assumes a 12x EBITDA multiple for Assurance but we apply a 20% discount to the group to account for the current uncertainty.
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
27 Feb 17
accesso expects full year profitability to be ahead of expectations. We have upgraded our Adj. PBT by 7% to $14.7m. The performance was achieved despite accelerated investment in “product and infrastructure to support business and growth opportunities in geographies outside its traditional core markets”. We see clear blue sky opportunity in the Asia-Pacific Market. We increase our T/P from 1850p to 1900p and maintain our Outperform recommendation.
N+1 Singer - dotdigital Group - Good H1; broadening avenues of growth
21 Feb 17
dotdigital delivered another good performance with H1’17 results showing 17% growth in revenues and 29% growth in PBT. Average monthly spend was up 24% as the group continues to move to the mid-market. We have made no changes to forecasts. Investments are being made to broaden its sources of growth both from a geographical and platform integration perspective. Additionally, the group flagged it is looking more closely at acquisitions that could accelerate its strategy. We believe the group remains well-placed to create further value with 81% recurring revenue, 3-yr EBITDA CAGR of 22%, £19m of net cash on the balance sheet, a positive demand environment and a track record of delivery.
N+1 Singer - IDOX - Positive AGM statement
24 Feb 17
Idox issued a positive AGM statement, indicating a strong start to the year, building on the performance and organic and acquisitive growth of 2016. It recently secured significant contracts in healthcare and transport and is continuing to win across other segments. The order book and pipeline, combined with a stable outlook across all its markets, support our positive view on the stock. We make no changes to our estimates which were recently upgraded for FY’16 results and the accretive 6PM acquisition. We believe the current 11.2x cal’17 EV/EBITDA rating is undemanding given its scale, profitability and outlook.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced